| Aug 6 |
Precigen Strategically Prioritizes Portfolio to Focus on First Potential Gene Therapy Launch
|
| Jul 31 |
Precigen, Inc.'s (NASDAQ:PGEN) Shift From Loss To Profit
|
| Jul 23 |
Precigen Appoints Phil Tennant as Chief Commercial Officer to Spearhead First Potential Gene Therapy Launch
|
| Jul 14 |
Precigen Insiders Added US$1.72m Of Stock To Their Holdings
|
| Jun 26 |
Is Precigen (NASDAQ:PGEN) In A Good Position To Invest In Growth?
|
| Jun 4 |
Precigen (NASDAQ:PGEN) shareholders are up 15% this past week, but still in the red over the last three years
|
| Jun 3 |
Precigen stock rallies 17% on data for PRGN-2012 gene therapy
|
| Jun 3 |
Precigen Announces Groundbreaking Pivotal Study Data for PRGN-2012 in Patients with Recurrent Respiratory Papillomatosis in Which More than Half of Patients Achieved Complete Response
|
| Jun 1 |
Investors Prep For A Key Jobs Report
|
| May 23 |
Precigen to Host a Webcast on June 3rd to Detail Pivotal Study Results of PRGN-2012 in Recurrent Respiratory Papillomatosis Presented at the 2024 ASCO Annual Meeting
|
